Pharma Industry Experts ask to Expand PLI scheme

Share Us

772
Pharma Industry Experts ask to Expand PLI scheme
28 Feb 2022
6 min read

News Synopsis

Leaders in the Indian pharmaceutical industry believe that they can extend the current Production-Linked Incentives (PLI) schemes for the pharmaceutical industry to link research in biologics and biosimilars.

Kiran Mazumdar Shaw, executive chairperson at Biocon Group has said that talked about the need for a different PLI scheme. She said that the new PLI scheme needs to focus on emerging opportunities for Indian pharma. 

The Rs 15,000 PLI scheme announced by the Centre includes three categories for companies. The quantum of incentives varies for all three groups. Till now, 55 drug manufacturers have been selected under the PLI scheme. 

Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines agrees has also said that if we look at our PLI scheme, a huge emphasis was given to ANDAs. He further said that there is not enough risk capital to encourage innovation.

ANDA contains data submitted to the USFDA for possible generic drug review and approval. In contrast, a bioproduct company submits a Biologics License Application (BLA), which is an application for permission to bring a pharmacy to the USA market.

TWN In-Focus